A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
Clinical trial NCT00845039 · TERMINATED
Trial details
- NCT number
- NCT00845039
- Sponsor
- Eli Lilly and Company
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-05-01
- Primary completion
- 2011-02-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.